In May 2026, the pharmaceutical industry faced an unprecedented regulatory policy package. The judicial interpretation from the Supreme People's Court and the Supreme People's Procuratorate, effective May 1, 2026, together with the Medical Representative Management Measures released by seven departments on May 7, marked the industry's official entry into an era of full-chain, closed-loop compliance supervision.
For pharmaceutical companies, every step of marketing activity is being brought under regulatory scrutiny. After the seven departments jointly issued the document, regulators made clear that joint disciplinary action would be implemented through information sharing, clue transfer, and coordination between administrative enforcement and criminal justice. At the same time, regulatory checks are moving from formal review to substantive review. The old era of "registration equals compliance" is over. Companies must not only keep records of marketing actions, but also prove the accuracy and authenticity of those records.
Behind every marketing action, compliance, professionalism, and transparency have become rigid requirements and may be checked by regulators at any time.
Master Data Accuracy: The First Line of Defense for Pharma Marketing Compliance
Driven by the new rules, pharmaceutical companies are facing a practical problem: if master data is inaccurate, the foundation of compliance management cannot stand.
- Academic promotion compliance requires companies to accurately identify every expert, institution, and activity content involved in each academic activity. Any information deviation may create compliance risk.
- Representative management compliance requires companies to clearly define every representative's authorization scope, promotion territory, and promotion field. Inaccurate data directly affects the management of representative behavior boundaries.
- Budget control compliance requires every marketing expense to have clear business justification and traceable records. Data quality directly determines expenditure compliance.
In reality, however, many pharmaceutical companies still face three major pain points in master data management: first, data sources are fragmented, with multiple vendors and business systems creating inconsistent data standards; second, data updates lag behind, so HCP information changes cannot be synchronized in time; third, manual operations are inefficient and accuracy is hard to guarantee, making large-scale master data verification almost impossible to complete manually.
As regulatory checks become stricter, these pain points are turning into real risks.
MeDomino Master Data Verification: Accurate, Fast, and Full-Lifecycle Management
With years of data management experience in the life sciences industry and strong AI algorithm capabilities, MeDomino provides professional and efficient master data verification services for pharmaceutical companies. Centered on compliance, professionalism, and transparency, MeDomino helps companies build master data management capabilities from the source and respond effectively to normalized regulatory checks.
MeDomino's master data verification service has two core advantages:
First, accurate data - a 4 million HCP database and AI-driven precision verification
MeDomino has a database covering more than 4 million HCPs across China. Based on long-term industry experience and self-developed AI algorithms, we have built a complete master data verification system for pharmaceutical companies. Through automated data collection, cleaning, and cross-verification, MeDomino can effectively identify and correct information errors, conflicts, and omissions in master data, ensuring data unity and consistency.
At the compliance level, the data is legal and compliant, results are quantifiable, and business departments highly recognize the value, providing reliable foundational data protection for pharmaceutical companies facing regulatory checks.
Second, faster speed - automated verification and scaled processing
Traditional master data verification often relies on extensive manual work. From data collection and cleaning to review, a large-scale verification round can take months. Through an AI-driven automated verification system, MeDomino can complete precise processing of massive data in a shorter time and efficiently break collected data into usable and analyzable information.
This means that when pharmaceutical companies face regulatory checks, internal audits, or business changes, master data verification and updates no longer slow the organization down. Instead, they become a support system that responds quickly and provides timely feedback.
Full-Lifecycle Management: More Than One-Time Verification
Beyond the core advantages of accuracy and speed, MeDomino also provides full-lifecycle master data management services from data collection, cleaning, and verification to continuous updates:
- HCP360 all-around profiles: integrate multi-source data to build a complete expert profile database.
- Intelligent KOL identification: use big data and AI algorithms to quickly and accurately identify target experts.
- Intelligent tagging and segmentation: connect master data precisely with business scenarios and support diverse needs such as clinical research and academic promotion.
Final Thoughts
2026 is a critical year for the comprehensive upgrade of pharmaceutical compliance supervision. As major regulations such as the judicial interpretation and the Medical Representative Management Measures take effect, "behind every marketing action are compliance, professionalism, and transparency, and it may be checked by regulators at any time" will become the industry's new normal. Compliance, professionalism, and transparency begin with accurate data. Accurate data needs professional capability to protect it.
MeDomino master data verification is committed to helping pharmaceutical companies build a strong compliance foundation at the master data management level and respond calmly to normalized regulatory checks. From data verification to profile building, from AI algorithms to business enablement, what MeDomino is doing is making compliance evidence-based and marketing traceable to its source.
Let every academic investment withstand inspection, and let every promotional activity be transparent and traceable. This is both a regulatory requirement and the future MeDomino and the industry look forward to together.
About MeDomino
MeDomino focuses on digital intelligence marketing technology for the life sciences industry. With the mission of "letting the right medical information be seen by the right people," we support pharma and medtech companies in transforming marketing toward compliance, professionalism, and transparency through HCP360 all-around profiling, automated master data verification, GEO optimization, AIGC content generation, and other services.
To learn more about master data verification solutions, contact us for a dedicated consultation.
